Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment with aminoglycosides

Xavier P. Estivill, Nancy Govea, Anna Barceló, Enric Perelló, Cèlia Badenas, Enrique Romero, Luis Moral, Rosaria Scozzari, Leila D'Urbano, Massimo Zeviani, Antonio Torroni

Research output: Contribution to journalArticle

394 Citations (Scopus)

Abstract

Hearing loss involves both genetic and environmental factors. A mutation (A1555G) in the mtDNA has been associated with aminoglycoside-induced and nonsyndromic sensorineural deafness. The pathological significance of this mutation in Caucasoid families has not been established, and its relationship with antibiotic treatment is not well understood. We studied 70 Spanish families with sensorineural deafness (36 congenital and 34 late onset) for the mtDNA A1555G mutation. The A1555G mutation was found in 19 families with maternally transmitted deafness but not in the other 51 families or in 200 control subjects. In 12 families all the patients with the A1555G mutation who received aminoglycosides became deaf, representing 30.3% of the deaf patients in these families. None of the deaf patients from seven other families received aminoglycosides. Overall, only 17.7% of the patients with deafness and the A1555G mutation had been treated with aminoglycosides. The age at onset of deafness was lower (median age 5 years, range 1-52 years) in those treated with aminoglycosides than in those who did not receive antibiotics (median age 20 years, range 1-65 years) (P < .001). The mtDNA of these families belongs to haplotypes common in Europeans. These data indicate that the A1555G mutation accounts for a large proportion of the Spanish families with late-onset sensorineural deafness, that the A1555G mutation has an age-dependent penetrance for deafness (enhanced by treatment with aminoglycosides), and that mtDNA backgrounds probably do not play a major role in disease expression.

Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalAmerican Journal of Human Genetics
Volume62
Issue number1
DOIs
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Aminoglycosides
Deafness
Mitochondrial DNA
Mutation
Therapeutics
Anti-Bacterial Agents
Penetrance
Hearing Loss
Age of Onset
Haplotypes

ASJC Scopus subject areas

  • Genetics

Cite this

Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment with aminoglycosides. / Estivill, Xavier P.; Govea, Nancy; Barceló, Anna; Perelló, Enric; Badenas, Cèlia; Romero, Enrique; Moral, Luis; Scozzari, Rosaria; D'Urbano, Leila; Zeviani, Massimo; Torroni, Antonio.

In: American Journal of Human Genetics, Vol. 62, No. 1, 1998, p. 27-35.

Research output: Contribution to journalArticle

Estivill, XP, Govea, N, Barceló, A, Perelló, E, Badenas, C, Romero, E, Moral, L, Scozzari, R, D'Urbano, L, Zeviani, M & Torroni, A 1998, 'Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment with aminoglycosides', American Journal of Human Genetics, vol. 62, no. 1, pp. 27-35. https://doi.org/10.1086/301676
Estivill, Xavier P. ; Govea, Nancy ; Barceló, Anna ; Perelló, Enric ; Badenas, Cèlia ; Romero, Enrique ; Moral, Luis ; Scozzari, Rosaria ; D'Urbano, Leila ; Zeviani, Massimo ; Torroni, Antonio. / Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment with aminoglycosides. In: American Journal of Human Genetics. 1998 ; Vol. 62, No. 1. pp. 27-35.
@article{1cef0d3c99404effa373357050aefbec,
title = "Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment with aminoglycosides",
abstract = "Hearing loss involves both genetic and environmental factors. A mutation (A1555G) in the mtDNA has been associated with aminoglycoside-induced and nonsyndromic sensorineural deafness. The pathological significance of this mutation in Caucasoid families has not been established, and its relationship with antibiotic treatment is not well understood. We studied 70 Spanish families with sensorineural deafness (36 congenital and 34 late onset) for the mtDNA A1555G mutation. The A1555G mutation was found in 19 families with maternally transmitted deafness but not in the other 51 families or in 200 control subjects. In 12 families all the patients with the A1555G mutation who received aminoglycosides became deaf, representing 30.3{\%} of the deaf patients in these families. None of the deaf patients from seven other families received aminoglycosides. Overall, only 17.7{\%} of the patients with deafness and the A1555G mutation had been treated with aminoglycosides. The age at onset of deafness was lower (median age 5 years, range 1-52 years) in those treated with aminoglycosides than in those who did not receive antibiotics (median age 20 years, range 1-65 years) (P < .001). The mtDNA of these families belongs to haplotypes common in Europeans. These data indicate that the A1555G mutation accounts for a large proportion of the Spanish families with late-onset sensorineural deafness, that the A1555G mutation has an age-dependent penetrance for deafness (enhanced by treatment with aminoglycosides), and that mtDNA backgrounds probably do not play a major role in disease expression.",
author = "Estivill, {Xavier P.} and Nancy Govea and Anna Barcel{\'o} and Enric Perell{\'o} and C{\`e}lia Badenas and Enrique Romero and Luis Moral and Rosaria Scozzari and Leila D'Urbano and Massimo Zeviani and Antonio Torroni",
year = "1998",
doi = "10.1086/301676",
language = "English",
volume = "62",
pages = "27--35",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment with aminoglycosides

AU - Estivill, Xavier P.

AU - Govea, Nancy

AU - Barceló, Anna

AU - Perelló, Enric

AU - Badenas, Cèlia

AU - Romero, Enrique

AU - Moral, Luis

AU - Scozzari, Rosaria

AU - D'Urbano, Leila

AU - Zeviani, Massimo

AU - Torroni, Antonio

PY - 1998

Y1 - 1998

N2 - Hearing loss involves both genetic and environmental factors. A mutation (A1555G) in the mtDNA has been associated with aminoglycoside-induced and nonsyndromic sensorineural deafness. The pathological significance of this mutation in Caucasoid families has not been established, and its relationship with antibiotic treatment is not well understood. We studied 70 Spanish families with sensorineural deafness (36 congenital and 34 late onset) for the mtDNA A1555G mutation. The A1555G mutation was found in 19 families with maternally transmitted deafness but not in the other 51 families or in 200 control subjects. In 12 families all the patients with the A1555G mutation who received aminoglycosides became deaf, representing 30.3% of the deaf patients in these families. None of the deaf patients from seven other families received aminoglycosides. Overall, only 17.7% of the patients with deafness and the A1555G mutation had been treated with aminoglycosides. The age at onset of deafness was lower (median age 5 years, range 1-52 years) in those treated with aminoglycosides than in those who did not receive antibiotics (median age 20 years, range 1-65 years) (P < .001). The mtDNA of these families belongs to haplotypes common in Europeans. These data indicate that the A1555G mutation accounts for a large proportion of the Spanish families with late-onset sensorineural deafness, that the A1555G mutation has an age-dependent penetrance for deafness (enhanced by treatment with aminoglycosides), and that mtDNA backgrounds probably do not play a major role in disease expression.

AB - Hearing loss involves both genetic and environmental factors. A mutation (A1555G) in the mtDNA has been associated with aminoglycoside-induced and nonsyndromic sensorineural deafness. The pathological significance of this mutation in Caucasoid families has not been established, and its relationship with antibiotic treatment is not well understood. We studied 70 Spanish families with sensorineural deafness (36 congenital and 34 late onset) for the mtDNA A1555G mutation. The A1555G mutation was found in 19 families with maternally transmitted deafness but not in the other 51 families or in 200 control subjects. In 12 families all the patients with the A1555G mutation who received aminoglycosides became deaf, representing 30.3% of the deaf patients in these families. None of the deaf patients from seven other families received aminoglycosides. Overall, only 17.7% of the patients with deafness and the A1555G mutation had been treated with aminoglycosides. The age at onset of deafness was lower (median age 5 years, range 1-52 years) in those treated with aminoglycosides than in those who did not receive antibiotics (median age 20 years, range 1-65 years) (P < .001). The mtDNA of these families belongs to haplotypes common in Europeans. These data indicate that the A1555G mutation accounts for a large proportion of the Spanish families with late-onset sensorineural deafness, that the A1555G mutation has an age-dependent penetrance for deafness (enhanced by treatment with aminoglycosides), and that mtDNA backgrounds probably do not play a major role in disease expression.

UR - http://www.scopus.com/inward/record.url?scp=17344365276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344365276&partnerID=8YFLogxK

U2 - 10.1086/301676

DO - 10.1086/301676

M3 - Article

C2 - 9490575

AN - SCOPUS:17344365276

VL - 62

SP - 27

EP - 35

JO - American Journal of Human Genetics

JF - American Journal of Human Genetics

SN - 0002-9297

IS - 1

ER -